Beijing Konruns Pharmaceutical (603590.SH) plans to launch a restricted stock incentive plan in 2026.
Kangchen Pharmaceuticals (603590.SH) disclosed the 2026 Restricted Stock Incentive Plan (draft), intending to grant 2.455 million restricted stocks to incentive recipients, accounting for 1.54% of the total equity of the company at the time of the announcement of the draft incentive plan. Of these, 2.275 million stocks will be granted initially, with 180,000 stocks reserved. The total number of incentive recipients to be initially granted is 63. The grant price for restricted stocks (including reserved stocks) is 15.75 yuan per share.
Beijing Konruns Pharmaceutical (603590.SH) disclosed its 2026 restricted stock incentive plan (draft). The number of restricted stocks proposed to be granted to incentive recipients is 2.455 million shares, accounting for 1.54% of the total share capital of the company at the time of the announcement of the incentive plan draft. Out of this, 2.275 million shares will be granted initially, with 180,000 shares reserved for future grants. The total number of intended recipients for the initial grant is 63 individuals. The grant price for the restricted stocks (including the reserved shares) is 15.75 yuan per share.
Related Articles
Xuancheng Valin Precision Technology (603356.SH) controlling shareholder intends to transfer 8% of the company's shares by agreement.
ZHONGSHENJIANYE (02503) issued 2.2886 billion shares.
CIRC(01763) and CNNC NUCLEAR SCIENCE AND TECHNOLOGY CO., LTD. established a joint venture company CNNC RADIATION ORIGIN.
Xuancheng Valin Precision Technology (603356.SH) controlling shareholder intends to transfer 8% of the company's shares by agreement.
ZHONGSHENJIANYE (02503) issued 2.2886 billion shares.
CIRC(01763) and CNNC NUCLEAR SCIENCE AND TECHNOLOGY CO., LTD. established a joint venture company CNNC RADIATION ORIGIN.
RECOMMEND
